Sareum Holdings Live Discussion

barno99 27 Sep 2016

Re: Further rise tomorrow 27.5% of $ 328 million is not to shabby. Especially as the current market cap is only £12 million..Search TPLLOGIN SUBSCRIBELEFTRIGHT1 OF 11READ ALL TODAY'S ISSUE IN FULLTODAY'S ISSUELeaderboardProNAi buys rights to cancer drug for up to $328.5 millionProNAi buys rights to cancer drug for up to $328.5 million27-09-2016 Comments (0)PrintUS clinical-stage drug development company ProNAi Therapeutics (Nasdaq: DNAI) has bought exclusive worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) for a figure which could reach $328.5 million.It has obtained an exclusive license from the CRT Pioneer Fund, a cancer investment fund established by Sixth Element Capital (6EC), Cancer Research Technology (CRT) and the European Investment Fund (EIF) and managed by 6EC.The deal caused a 150% rise in the share price of Sareum Holdings (AIM: SAR), a cancer drug discovery and development company and co-investment partner of the CRT Pioneer Fund, though the stock has since stabilized."PNT737 targets the DNA damage response network, a promising approach to treating cancer based on recent leading-edge discoveries in cancer"Under the terms of the agreement, an immediate upfront payment of $7 million is due to the co-investment partners and an additional fee of up to US$2 million will be payable upon the successful transfer of the two ongoing Phase I clinical trials to ProNAi.Additional payments in the aggregate amount of up to $319.5 million may become payable upon achievement of certain development, regulatory and commercial milestones. ProNAi will also owe high single to low double digit royalties on the net sales of any product successfully developed.PNT737 was originally developed in a research collaboration between the Institute of Cancer Research, London, Sareum and Cancer Research Technology. The Program was licensed to the CRT Pioneer Fund in September 2013 and a co-investment partnership with Sareum was formed to progress the candidate drug through clinical trials.Nick Glover, chief executive of ProNAi, said: “This transaction adds another high-quality asset to our pipeline based on recent leading-edge discoveries in cancer biology. PNT737 targets the DNA damage response network, a promising approach to treating cancer based on recent leading-edge discoveries in can."“Cancer cells often depend on activated Chk1, a central cell cycle checkpoint regulator in the DDR network, as a strategy to survive and replicate despite accumulating extensive DNA damage due to replicative stress or in response to chemotherapeutic intervention. PNT737 is a potent and selective inhibitor of Chk1 that targets a potential Achilles' heel of cancer cell proliferation and survival.”Robert James, managing partner of 6EC, said: “This is another significant milestone on the development path for this promising Chk1 inhibitor. We recently initiated a Phase I single agent monotherapy study and a Phase I study of PNT737 in combination with DNA-targeting chemotherapies. ProNAi has a world-class oncology development team and is well-capitalized, and we believe these studies and the ongoing development strategy for this drug are in excellent hands.”Tim Mitchell, chief executive of Sareum, which is due to receive 27.5% of payments from the deal, said: “This is a major achievement for our lead candidate as well as for Sareum. Starting with the initial discovery, we have contributed financially and scientifically to the ongoing development of the program into clinical trials. The returns from this research investment will be realized in this licence agreement, validating our strategy and business model.“ProNAi is in a strong position to further the development of PNT737 and plans to expand its development into the USA and with broader clinical studies. We look forward to reporting on their progress.”BiotechnologyDealsLicensingOncologyPNT737ProNAi TherapeuticsResea

alltold9 27 Sep 2016

Re: Further rise tomorrow A real life changer. Just re read the RNS and it has unbelievable implications for so many. Lets see double figures as just a start. Happy days ahead for both punters and end users.

alltold9 27 Sep 2016

Re: Further rise tomorrow Yes we could easily see 2p+ in early trading!

asilad 27 Sep 2016

Further rise tomorrow After that strong finish another chunky rise should be on the cards for tomorrow with a little bit of luck.

geldman 27 Sep 2016

At last!! My last sale was at 4.45p in Feb 2011, so we have some way to go to match that BUT I sold enough of my holding that I have been playing with the bookies' money since then. Encouraging news because potential long term flows of royalty payments=dividends in the future.I have no idea as to what else is in the pipeline but this is the first encouraging news for several years. Watch out for large bonus payments in the next accounts and/or options being exercised by management.

asilad 27 Sep 2016

Re: So What Now? Yes I suppose so, although I was honestly expecting a 200% plus rise off the back of that kind of news. Perhaps over the next few weeks it will come as others note the news.

barno99 27 Sep 2016

Re: So What Now? Sounds good to me... The royalties will come in for years and years. Some very hefty payments so all sounds great to me.

asilad 27 Sep 2016

So What Now? Leading drug prospect sold off for payments/future royalties and a 100% plus rise to put them up to a share price they were at 3 years ago, albeit with half the amount of shares currently issued.Is that it?

barno99 27 Sep 2016

Canada news ... ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) From CRT Pioneer Fund, UK Share with Twitter Share with LinkedIn VANCOUVER, Canada, September 27, 2016 /PRNewswire/ --- PNT737 Currently in Phase 1 Clinical Trials at the Royal Marsden, London, UK- Potential to Exploit Cancer-Driving Genetic Mutations to Achieve Synthetic Lethality- Broad Development Opportunities in Combination With DNA Damage-Inducing ChemotherapiesProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1). PNT737 is being investigated in two recently initiated Phase 1 clinical trials, currently sponsored and managed by the Cancer Research UK Centre for Drug Development, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust. (ClinicalTrials.gov identifiers: NCT02797977 and NCT02797964).Under the terms of the agreement, ProNAi will pay the CRT Pioneer Fund an upfront payment of US$7.0 million. ProNAi will take on sponsorship and management of the clinical development of the agent from Cancer Research UK's Centre for Drug Development and pay a fee of up to $2.0 million upon the successful transfer of the two ongoing Phase 1 clinical trials to the Company. Additional payments in the aggregate amount of up to US$319.5 million may become payable upon achievement of certain development, regulatory and commercial milestones. ProNAi will also owe CRT Pioneer Fund high single to low double digit royalties on net sales."This transaction adds another high-quality asset to our pipeline. PNT737 targets the DNA Damage Response (DDR) network, a promising approach to treating cancer based on recent leading-edge discoveries in cancer biology," said Dr. Nick Glover, President and CEO of ProNAi. "Cancer cells often depend on activated Chk1, a central cell cycle checkpoint regulator in the DDR network, as a strategy to survive and replicate despite accumulating extensive DNA damage due to replicative stress or in response to chemotherapeutic intervention. PNT737 is a potent and selective inhibitor of Chk1 that targets a potential Achilles' heel of cancer cell proliferation and survival."PNT737 was discovered and initially developed by scientists in the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) in collaboration with Sareum Holdings plc (LSE AIM: SAR), with funding provided by Cancer Research UK, the ICR and Sareum. The program was licensed in September 2013 to the CRT Pioneer Fund, a specialist cancer investment fund established by Sixth Element Capital LLP (6EC), Cancer Research Technology (CRT) and the European Investment Fund (EIF) and managed by 6EC."This is another significant milestone on the development path for this promising Chk1 inhibitor. We recently initiated a Phase 1 single agent monotherapy study and a Phase 1 study of PNT737 in combination with DNA-targeting chemotherapies. ProNAi has a world-class oncology development team and is well-capitalized, and we believe these studies and the ongoing development strategy for this drug are in excellent hands," added Robert James, Managing Partner of 6EC.Dr. Udai Banerji, Cancer Research UK Reader in Molecular Cancer Pharmacology at the ICR and Consultant at The Royal Marsden, stated: "This is an exciting opportunity to investigate a novel anticancer agent targeting the aberrant tumor DDR pathway. Two PNT737 clinical trials are now underway and, as Principal Investigator of these studies, I look forward to working closely with ProNAi to optimize the development path for this promising drug candidate."Professor Paul Work

barno99 27 Sep 2016

No idea how sell came up .. Should be strong buy.Pro active..HomeNewsArticlesLON:SARSareum shares rocket after ProNAi Therapeutics licenses cancer drugShare 12:44 27 Sep 2016Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.Cancer cell graphic“This is a major achievement for our lead candidate as well as for Sareum."Shares in Sareum Holdings PLC (LON:SAR) rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics, Inc (NASDAQNAI).Under Sareum’s agreements with Cancer Research Technology (CRT) and the CRT Pioneer Fund, the drug discovery group will receive US$1.9mln as an up-front payment and potential future milestone payments of up to US$88.4mln, some of which will be paid within the next year.Sareum’s Chk1 Inhibitor CCT245737 (to be renamed PNT737) was originally developed in a research collaboration between the London Institute of Cancer Research, Sareum and CRT.The ChK1 or checkpoint kinase 1 inhibitor is shown to prevent cancer cells from multiplying by attacking its faulty DNA, meaning the cancer self-destructs.The group sees potential for synergy between standard cancer therapies - such as radio- or chemotherapy - and checkpoint inhibitors as a combination therapy.“This is a major achievement for our lead candidate as well as for Sareum. Starting with the initial discovery, we have contributed financially and scientifically to the on-going development of the programme into clinical trials. The returns from this research investment will be realised in this licence agreement, validating our strategy and business model,” said chief executive Tim Mitchell.“ProNAi is in a strong position to further the development of PNT737 and plans to expand its development into the United States and with broader clinical studies. We look forward to reporting on their progress,” he added."ProNAi has a world-class oncology development team and is well-capitalised, and we believe these studies and the ongoing development strategy for this drug are in excellent hands,” said Robert James of Sixth Element Capital LLP, managers of the CRT Pioneer Fund.Shares shot up 150% to a three-year high of 1.56p. Share Josh.jpgJosh AllsoppWHY INVEST IN SAREUM HOLDINGS PLC? READ MORE HERE REGISTER HERE TO BE NOTIFIED OF FUTURE SAR COMPANY ARTICLES

barno99 27 Sep 2016

Where's the target now then. Happy is not the word really...This could easily be a 10-20 multiple share very quickly.Wow!!

Chard Nick 27 Sep 2016

Re: news Tuesday, watch this space Only a month out!!Well done, anyway.CN - Finally at break-even

alltold9 27 Sep 2016

5p+ Target! As a minimum to me, added to SOU and SOLG. Happy days.

velocipede 27 Sep 2016

Re: Now up 152% - veloc I like to think of it as just reaching the peak of the first foothill if you like. I already owned these for five years, so must be patient! You're right of course, but luckily it's just a bit of spare change from my solgold profits. That and Sound Oil keeping my losers afloat at the moment.

asilad 27 Sep 2016

Re: Now up 152% - veloc The top of the price rise. Peaked at 1.64 for now.